9.30 | 6.30 – Virtual Coffee Networking Morning


Grab your morning coffee and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

10.00 | 7.00 – Chair’s Opening Remarks: Progress Seen Over the Past 12 Months & Why We Should Be Excited About What’s on the Horizon


  • CTCs, circulating nucleic acids, exosomes and proteomics: Changing trends in the liquid biopsy for precision oncology space
  • What can recent FDA approvals tell us about future opportunities for the industry to grow?
  • Which new clinical applications for liquid biopsies are on the horizon for 2021?

Technological Advances Supporting Clinical Trial Data Collection

10.15 | 7.15 – Accurate Biomarker Identification Through Digital Sequencing: Accelerating Adoption of ctDNA in Trials & the Clinic


  • Lessons from 100,000 patients to improve assay performance
  • Clinical trial case studies for faster enrollment and study insights
  • Improving patient treatment and outcomes

10.45 | 7.45 – Integrating Liquid Biopsy as Part of a Clinical Development Strategy

  • Howard I. Scher, MD, FASCO Head, Biomarker Development Program Attending Physician Department of Medicine, Memorial Sloan Kettering Cancer Center


  • Identifying opportunities in targeted therapeutic development where liquid biopsies work to compliment efficacy demonstration and perceived safety profile of a therapeutic in a target population
  • Which challenges have been identified and been successfully overcome conducting trials incorporating liquid profiling assays?
  • The future of liquid biopsies: Complementing or replacing the tissue as the ‘gold standard’

11.15 | 8.15 – Panel Discussion: Women & Diversity in Precision Healthcare


This panel discussion is designed to bring value to all leaders in healthcare looking to unlock the potential of their team, career and business. Through tapping into multiple diverse perspectives and experiences we can accelerate innovation and drive progress in the provision of care.

12.00 | 9.00 – Speed Networking Break


Grab a morning coffee/tea and enjoy this whilst meeting fellow industry and academic experts. An opportunity to network, discuss and collaborate with like-minded leaders, enjoyed from the comfort of your own home!

12.30 | 9.30 – New Technologies for Detection of Circulating-DNA Biomarkers, With Minimal Sample Size Requirement

  • Mike Makrigiorgos Professor and Director, Medical Physics & Biophysics Division, Harvard Medical School


  • As the potential of liquid biopsies for prognostic, predictive or early cancer detection applications grows, so does the demand for technical advances to accompany the burgeoning range of applications
  • We present new developments that enable targeted re-sequencing for liquid biopsy applications at a fraction of the current sample size and cost, while retaining sensitivity and specificity
  • Examples for detecting microsatellite instability and low-level mutations
    in circulating DNA will be presented

13.00 | 10.00 – Session Reserved for Foundation Medicine

13.30 | 10.30 – Panel Discussion led by Foundation Medicine

14.00 | 11.00 – Detection & Utility of Blood-Based Biomarkers in IO

  • Jonathan Badan Senior Director, Pharmacodiagnostics & Precision Medicine, Bristol-Myers Squibb


  • ctDNA Applications for Early and Late Stage disease
  • Current and Emerging Technologies
  • Utilization of Blood-Based Biomarkers in Clinical Trials

14.30 | 11.30 – Networking Break – Whilst enjoying a bite to eat, you can take part in:


  • 121 Pre-Scheduled Meetings With Our Event Partners: Take part in 1:1 networking with market leaders pioneering exciting advances in the liquid biopsy space
  • Group Networking: Join your fellow attendees for groups discussions reflecting on the morning’s topics. Collaborate and connect to consider applying new ideas and innovations to propel your pipelines forward.

Creating Consistency in Pre-Analytical Protocols & Downstream Analysis

15.00 | 12.00 – A Public-Private Consortium to Develop Quality Control Materials for Circulating Tumor DNA

  • Chris Karlovich Associate Director, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer


  • The goal of the FNIH Quality Control Material (QCM) project is to develop a universal set of well-vetted, quality control materials (QCMs) for the liquid biopsy community
  • The project is proceeding in 3 phases; Phase 1, a performance evaluation of the QCMs, is complete and the results will be presented
  • Phase 2 (a functional characterization study) and Phase 3 (a real-world clinical pilot of the QCMs in 10 academic and commercial laboratories) are in the planning stages and the designs will be presented

15.30 | 12.30 – An Update From BloodPAC: Defining Industry Standards in Testing Technologies for Reproducible Results


  • A review of pre-analytical minimal technical data elements (MTDEs) affecting assay result
  • Working towards reproducibility and repeatability of testing by creating industry-wide standards
  • Addressing patient and clinical context variables

16.00 | 13.00 – Chair’s Closing Remarks

16.10 | 13.10 – Networking Reception Led by Guardant Health